← All trials
NCT06496308
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jul 10, 2024
- Primary completion
- Jul 10, 2027
- Completion date
- Jul 10, 2027
- First posted
- Jul 11, 2024
- Last posted
- Jul 11, 2024
- Enrollment
- 78
- Arms / groups
- 4 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Jiao Tong UniversityLead sponsor
- Fujian Medical UniversityCollaborator
- Fujian Medical UniversityCollaborator
- Jiangxi Provincial Cancer HospitalCollaborator
- Central South UniversityCollaborator
- Qingdao UniversityCollaborator
- Jiao Tong UniversitySponsor investigator
- Anhui Medical UniversityCollaborator
- Anhui Medical UniversityCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.